Galectin Therapeutics (NASDAQ:GALT) Insider Khurram Jamil Sells 121,117 Shares of Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) insider Khurram Jamil sold 121,117 shares of the business’s stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $5.47, for a total transaction of $662,509.99. Following the completion of the transaction, the insider owned 4,479 shares of the company’s stock, valued at approximately $24,500.13. This represents a 96.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Galectin Therapeutics Price Performance

GALT stock traded down $0.02 during midday trading on Friday, hitting $5.51. 238,869 shares of the stock traded hands, compared to its average volume of 390,645. Galectin Therapeutics Inc. has a 1-year low of $0.73 and a 1-year high of $6.55. The stock’s fifty day simple moving average is $5.00 and its 200-day simple moving average is $3.39. The firm has a market cap of $355.28 million, a P/E ratio of -8.61 and a beta of 0.86.

Galectin Therapeutics (NASDAQ:GALT) last posted its earnings results on Friday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, research analysts predict that Galectin Therapeutics Inc. will post -0.73 earnings per share for the current year.

Institutional Trading of Galectin Therapeutics

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in Galectin Therapeutics by 2.9% in the 3rd quarter. Vanguard Group Inc. now owns 2,247,967 shares of the company’s stock valued at $9,520,000 after acquiring an additional 63,419 shares during the last quarter. Osaic Holdings Inc. boosted its stake in Galectin Therapeutics by 3.4% during the second quarter. Osaic Holdings Inc. now owns 1,265,384 shares of the company’s stock worth $2,670,000 after buying an additional 41,968 shares during the last quarter. Jane Street Group LLC purchased a new stake in Galectin Therapeutics in the 2nd quarter valued at $1,580,000. Wealthspire Advisors LLC grew its holdings in Galectin Therapeutics by 20.4% in the 2nd quarter. Wealthspire Advisors LLC now owns 479,518 shares of the company’s stock valued at $1,012,000 after buying an additional 81,144 shares in the last quarter. Finally, Geneos Wealth Management Inc. increased its stake in shares of Galectin Therapeutics by 8.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 423,235 shares of the company’s stock worth $516,000 after acquiring an additional 34,300 shares during the last quarter. Hedge funds and other institutional investors own 11.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on GALT shares. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Galectin Therapeutics in a research report on Thursday, August 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Galectin Therapeutics in a research note on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $6.00.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.